Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.

摘要: UNLABELLED Pramipexole is an orally active non-ergoline dopamine agonist with selective activity at receptors belonging to the D2 receptor subfamily (D2, D3, D4 subtypes) and preferential affinity for D3 subtype. It approved as monotherapy in early Parkinson's disease adjunctive therapy levodopa patients advanced experiencing motor effects because of diminished response levodopa. The potential neuroprotective pramipexole have been shown animal vitro studies. Data from relatively long term (10- or 31-week) studies suggest that (0.375 6.0 mg/day) can improve activities daily living symptoms disease. 4.5 mg/day 31 36 weeks), adjunct disease, improved symptoms, reduced duration severity 'off' periods allowed a reduction dosage. Mentation, behaviour mood [Unified Disease Rating Scale (UPDRS) part I], timed walking test were not significantly improved. extent disability according UPDRS parts II III but, when assessed by secondary efficacy parameters, it unclear whether No significant differences observed randomised bromocriptine hypothesis prospective study which both drugs better than placebo. Some quality-of-life measures treatment relative Further comparing other agonists would be useful. In recipients most commonly experienced adverse events nausea, dizziness, somnolence, insomnia, constipation, asthenia hallucinations. reported orthostatic hypotension, dyskinesias, extrapyramidal syndrome (defined worsening disease), hallucinations, accidental injury, dream abnormalities, confusion, asthenia, dystonia, gait abnormality, hypertonia, dry mouth, amnesia urinary frequency. incidence some did greatly differ between placebo recipients. CONCLUSIONS effective However, beneficial on progression need confirmed clinical has also demonstrated, although use remains controversial.